Real‐World Comparison of Vedolizumab and Ustekinumab in TNF Inhibitor–Experienced Ulcerative Colitis Patients Followed by Therapeutic Drug Monitoring
JCC Plus · 2026
DOI: 10.1002/jcc5.70011 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCC Plus, 2026. Verfasst von Thea H. Wiken und 8 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims Vedolizumab and ustekinumab are alternative therapies in patients with ulcerative colitis (UC) previously exposed to TNF inhibitors (TNFi). In Norway, treatment follows a national tender, and vedolizumab was first choice after TNFi discontinuation from 2016 to 2019 and ustekinumab from 2020 to 2022. We aimed to compare one‐year real‐world effectiveness of vedolizumab or ustekinumab in TNFi‐experienced UC patients followed by therapeutic drug monitoring.
Methods
This single‐center study included adult TNFi‐exposed UC patients treated with vedolizumab (2016–2019) or ustekinumab (2020–2022). Clinical remission was defined as 6‐point Mayo score ≤ 1, steroid‐free clinical remission as clinical remission, no steroid use 2 weeks prior to date of hospital visit, and biochemical remission as C‐reactive protein < 5 mg/L and fecal calprotectin < 250 μg/g. Targeted serum values were > 5 mg/L (ustekinumab) and > 20 mg/L (vedolizumab). Between‐cohort baseline differences were adjusted for in the analyses.
Results
Of 109 patients (52 vedolizumab and 57 ustekinumab), vedolizumab patients were less likely to achieve steroid‐free clinical and biochemical remission at 6 months (adjusted OR (aOR) = 0.3, 95% CI [0.1–0.9] and aOR = 0.2, [0.1–0.7], respectively). No difference in remission rates was found at 12 months. A higher proportion of ustekinumab patients received intensified dosing at 12 months (87% vs. 57%, aOR = 0.2, [0.06–0.6]).
Conclusions
Twelve‐month effectiveness was similar for the two drugs. Ustekinumab patients were more likely to achieve steroid‐free clinical and biochemical remission at 6 months, with a greater proportion requiring dose intensification to reach target drug levels.
Zitieren
APA
Wiken, T. H., Høivik, M. L., Anisdahl, K., Buer, L., Moum, B. A., Warren, D. J., Bolstad, N., Hagen, M., & Medhus, A. W. (2026). Real‐World Comparison of Vedolizumab and Ustekinumab in TNF Inhibitor–Experienced Ulcerative Colitis Patients Followed by Therapeutic Drug Monitoring. JCC Plus. https://doi.org/10.1002/jcc5.70011
Vancouver
Wiken TH, Høivik ML, Anisdahl K, Buer L, Moum BA, Warren DJ, et al. Real‐World Comparison of Vedolizumab and Ustekinumab in TNF Inhibitor–Experienced Ulcerative Colitis Patients Followed by Therapeutic Drug Monitoring. JCC Plus. 2026. doi:10.1002/jcc5.70011
BibTeX
@article{Wiken2026,
author = {Wiken, Thea H. and Høivik, Marte L. and Anisdahl, Karoline and Buer, Lydia and Moum, Bjørn A. and Warren, David J. and Bolstad, Nils and Hagen, Milada and Medhus, Asle W.},
title = {Real‐World Comparison of Vedolizumab and Ustekinumab in TNF Inhibitor–Experienced Ulcerative Colitis Patients Followed by Therapeutic Drug Monitoring},
journal = {JCC Plus},
year = {2026},
doi = {10.1002/jcc5.70011}
}
EUVIMED